STX — Shield Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- £11.54m
- £3.71m
- £5.49m
- 24
- 46
- 13
- 16
Annual cashflow statement for Shield Therapeutics, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
C2018 December 31st | 2019 December 31st | 2020 December 31st | C2021 December 31st | R2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | Interim Report |
| Standards: | — | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -1.79 | -8.8 | -2.63 | -19.7 | -49.4 |
| Depreciation | |||||
| Non-Cash Items | -2.35 | 0.254 | 1.24 | 0.41 | 18.7 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.6 | 1.86 | -2.71 | -1.2 | 6.38 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 0.151 | -4.07 | -1.4 | -18.3 | -21.5 |
| Capital Expenditures | -3.35 | -1.38 | -0.023 | -2.06 | -2.29 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.05 | 0.018 | 0.003 | 0.013 | 0.036 |
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -3.29 | -1.37 | -0.02 | -2.05 | -2.25 |
| Financing Cash Flow Items | -0.379 | -0.229 | -0.005 | -0.045 | -0.408 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -0.379 | -0.203 | -0.047 | 27.7 | 9.37 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -3.52 | -5.63 | -1.2 | 9.18 | -13 |